Sutter Davis Hospital
- Type
- Teaching hospital
- Where
- Davis, CA
- Medicare CCN
- 050537
- Received
- $126,376 in 35 records, 2025 ($78 general, $126,297 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 3 | $78 |
| 2025 | Research payment | 32 | $126,297 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 8 | $45,133 | 2025 |
| Abbott Laboratories | 10 | $41,989 | 2025 |
| Genentech, Inc. | 2 | $17,367 | 2025 |
| Ethicon Endo-Surgery Inc. | 6 | $15,550 | 2025 |
| BioMarin Pharmaceutical Inc. | 1 | $3,999 | 2025 |
| MEDIVATION LLC. | 5 | $2,258 | 2025 |
| Bio-Rad Laboratories, Inc. | 3 | $78 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 32 | $126,297 |
| Debt forgiveness | 3 | $78 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | PFIZER INC. | $4,754 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO | 2025 | |
| 2025-12-27 | PFIZER INC. | $4,779 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO | 2025 | |
| 2025-12-08 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2025 |
| 2025-12-01 | Ethicon Endo-Surgery Inc. | $3,886 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2025 |
| 2025-11-26 | Abbott Laboratories | $1,234 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-11-25 | PFIZER INC. | $4,499 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO | 2025 | |
| 2025-11-05 | Abbott Laboratories | $2,707 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-10-27 | Abbott Laboratories | $3,098 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Cardiac Rhythm Management | NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Hea | 2025 |
| 2025-10-27 | Abbott Laboratories | $65 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Cardiac Rhythm Management | NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Hea | 2025 |
| 2025-10-01 | BioMarin Pharmaceutical Inc. | $3,999 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature | 2025 |
| 2025-08-18 | Abbott Laboratories | $5,645 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-08-11 | Abbott Laboratories | $5,869 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-08-08 | Ethicon Endo-Surgery Inc. | $1,737 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2025 |
| 2025-06-26 | PFIZER INC. | $17,500 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO | 2025 | |
| 2025-06-25 | Abbott Laboratories | $6,368 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-06-09 | Genentech, Inc. | $1,367 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2025 |
| 2025-06-02 | MEDIVATION LLC. | $250 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-02 | MEDIVATION LLC. | $250 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-12 | Abbott Laboratories | $4,474 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-05-12 | Ethicon Endo-Surgery Inc. | $307 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2025 |
| 2025-05-05 | MEDIVATION LLC. | $586 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-05 | MEDIVATION LLC. | $586 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-04-11 | Ethicon Endo-Surgery Inc. | $579 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2025 |
| 2025-04-02 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | PFIZER REGISTRY OF OUTCOMES IN GROWTH HORMONE RESEARCH PROGRES A MULTI COUNTRY NONINTERVENTIONAL PROSPECTIVE COHORT STUD | 2025 | |
| 2025-03-17 | Abbott Laboratories | $6,904 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT03904147--TRILUMINATE Pivotal Trial | 2025 |
| 2025-03-10 | Ethicon Endo-Surgery Inc. | $1,158 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2025 |
| 2025-03-03 | MEDIVATION LLC. | $586 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-02-24 | Abbott Laboratories | $5,621 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-02-06 | Ethicon Endo-Surgery Inc. | $7,883 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2025 |
| 2025-02-04 | Genentech, Inc. | $16,000 | Research payment | Cash or cash equivalent | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | 2025 | |
| 2025-02-03 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA | 2025 | |
| 2025-01-31 | PFIZER INC. | $350 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2025 |
| 2025-01-09 | Bio-Rad Laboratories, Inc. | $32 | Debt forgiveness | Cash or cash equivalent | D10 Device, Diabetes | 2025 | |
| 2025-01-09 | Bio-Rad Laboratories, Inc. | $32 | Debt forgiveness | Cash or cash equivalent | D-100 Device, Diabetes | 2025 | |
| 2025-01-09 | Bio-Rad Laboratories, Inc. | $13 | Debt forgiveness | Cash or cash equivalent | D-100 Device, Diabetes | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Davis, CA, county Yolo County, CA, state California; placed by its city name.
| Measure | Place (city or town) Davis, CA | County Yolo County, CA | State California |
|---|---|---|---|
| Population B01003 | 66,978 | 220,564 | 39,287,377 |
| Population, 2020 census P1 | 66,850 | 216,403 | 39,538,223 |
| Median age B01002 | 26.4 | 32.1 | 37.9 |
| Under 18 B01001 | 13.5% | 20.1% | 22.0% |
| 65 and over B01001 | 14.0% | 13.5% | 15.7% |
| Households B11001 | 25,358 | 76,693 | 13,548,091 |
| Foreign born B05002 | 19.0% | 21.0% | 27.0% |
| Median household income B19013 | $90,045 | $91,752 | $99,122 |
| Median family income B19113 | $169,957 | $122,185 | $113,346 |
| Per capita income B19301 | $51,329 | $43,733 | $49,513 |
| Poverty rate B17001 | 26.5% | 16.7% | 12.0% |
| Unemployment rate B23025 | 6.3% | 6.1% | 6.6% |
| Civilian labor force B23025 | 35,370 | 111,266 | 20,068,466 |
| Mean commute (minutes) B08013 | 22.3 | 24.0 | 28.7 |
| Bachelor's degree or higher B15003 | 76.8% | 44.8% | 37.1% |
| Housing units B25001 | 27,484 | 82,447 | 14,644,735 |
| Owner-occupied B25003 | 43.5% | 54.3% | 55.9% |
| Renters B25003 | 56.5% | 45.7% | 44.1% |
| Median home value B25077 | $866,100 | $620,700 | $734,700 |
| Median gross rent B25064 | $2,187 | $1,857 | $2,036 |
| White, not Hispanic B03002 | 49.9% | 41.8% | 33.8% |
| Black B03002 | 2.2% | 2.4% | 5.2% |
| Hispanic or Latino B03002 | 15.1% | 33.4% | 40.2% |
| Asian B03002 | 24.2% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.4% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Davis, CA.
Comments